BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30195235)

  • 1. Flexibility enables to discriminate between ligands: Lessons from structural ensembles of Bcl-xl and Mcl-1.
    Maity A; Majumdar S; Ghosh Dastidar S
    Comput Biol Chem; 2018 Dec; 77():17-27. PubMed ID: 30195235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X
    Reddy CN; Manzar N; Ateeq B; Sankararamakrishnan R
    Biochemistry; 2020 Nov; 59(45):4379-4394. PubMed ID: 33146015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
    Modi V; Sankararamakrishnan R
    J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
    Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
    Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins.
    Desrat S; Remeur C; Roussi F
    Org Biomol Chem; 2015 May; 13(19):5520-31. PubMed ID: 25877523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytosterols and triterpenes from
    Adewole KE; Ishola AA
    J Recept Signal Transduct Res; 2019 Feb; 39(1):87-97. PubMed ID: 31215288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
    Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
    J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1.
    Desrat S; Pujals A; Colas C; Dardenne J; Gény C; Favre L; Dumontet V; Iorga BI; Litaudon M; Raphaël M; Wiels J; Roussi F
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5086-8. PubMed ID: 25266781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins.
    Desrat S; Remeur C; Gény C; Rivière G; Colas C; Dumontet V; Birlirakis N; Iorga BI; Roussi F
    Chem Commun (Camb); 2014 Aug; 50(62):8593-6. PubMed ID: 24956071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.
    Gloaguen C; Voisin-Chiret AS; Sopkova-de Oliveira Santos J; Fogha J; Gautier F; De Giorgi M; Burzicki G; Perato S; Pétigny-Lechartier C; Simonin-Le Jeune K; Brotin E; Goux D; N'Diaye M; Lambert B; Louis MH; Ligat L; Lopez F; Juin P; Bureau R; Rault S; Poulain L
    J Med Chem; 2015 Feb; 58(4):1644-68. PubMed ID: 25585174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-apoptotic carboxamide analogues of natural fislatifolic acid targeting Mcl-1 and Bcl-2.
    Gapil Tiamas S; Daressy F; Abou Samra A; Bignon J; Steinmetz V; Litaudon M; Fourneau C; Hoong Leong K; Ariffin A; Awang K; Desrat S; Roussi F
    Bioorg Med Chem Lett; 2020 Apr; 30(7):127003. PubMed ID: 32035700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Affimers Recognise the BCL-2 Family Proteins BCL-x
    Miles JA; Hobor F; Trinh CH; Taylor J; Tiede C; Rowell PR; Jackson BR; Nadat FA; Ramsahye P; Kyle HF; Wicky BIM; Clarke J; Tomlinson DC; Wilson AJ; Edwards TA
    Chembiochem; 2021 Jan; 22(1):232-240. PubMed ID: 32961017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
    Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
    Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the BH3 Binding Interface of Bcl-xL, Bcl-2, and Mcl-1 Using Split-Luciferase Reassembly.
    Campbell ST; Carlson KJ; Buchholz CJ; Helmers MR; Ghosh I
    Biochemistry; 2015 Apr; 54(16):2632-43. PubMed ID: 25844633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.
    Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S
    ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.
    Hedir S; De Giorgi M; Fogha J; De Pascale M; Weiswald LB; Brotin E; Marekha B; Denoyelle C; Denis C; Suzanne P; Gautier F; Juin P; Ligat L; Lopez F; Carlier L; Legay R; Bureau R; Rault S; Poulain L; Oliveira Santos JS; Voisin-Chiret AS
    Eur J Med Chem; 2018 Nov; 159():357-380. PubMed ID: 30308410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.
    Beekman AM; Howell LA
    ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
    Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
    Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.